<DOC>
	<DOCNO>NCT01807585</DOCNO>
	<brief_summary>This randomize control trial compare VenaSeal Sapheon Closure System Radiofrequency Ablation .</brief_summary>
	<brief_title>VenaSeal Sapheon Closure System Pivotal Study</brief_title>
	<detailed_description>To demonstrate safety effectiveness VenaSeal SCS non-inferior RF ablation therapy achieve anatomical closure lower extremity superficial truncal vein patient venous reflux endovascular transcatheter embolization coaptation great saphenous vein ( GSV ) reduction intraprocedural post procedural pain symptom . The study demonstrate safety VenaSeal SCS follow-up visit evaluate via duplex ultrasound physical exam presence deep vein thrombosis pulmonary embolus .</detailed_description>
	<criteria>1 . Age ≥21 year ≤ 70 year age time screen 2 . Reflux great saphenous vein ( GSV ) great 0.5 sec reflux 3 . One follow symptom related target vein : aching , throb , heaviness , fatigue , pruritis , night cramp , restlessness , generalize pain discomfort , swell 4 . GSV diameter stand 312 mm throughout target vein measure Duplex ultrasound . 5 . CEAP classification C2 ( symptomatic ) C4b 6 . Ability walk unassisted 7 . Ability attend followup visit 8 . Ability understand requirement study provide inform consent . 1 . Life expectancy &lt; 1 year 2 . Active treatment malignancy nonmelanoma skin cancer 3 . Symptomatic peripheral arterial disease ABI &lt; 0.89 4 . Daily use narcotic nonsteroidal antiinflammatory pain medication control pain associate GSV reflux . 5 . Current , regular use systemic anticoagulation ( e.g. , warfarin , heparin ) 6 . Previous suspect deep vein thrombosis ( DVT ) pulmonary embolus ( PE ) . 7 . Previous superficial thrombophlebitis GSV . 8 . Previous treatment venous disease target limb , spider vein treatment . 9 . Known hypercoagulable disorder . 10 . Conditions prevent vein treatment 11 . Immobilization inability ambulate 12 . Pregnant prior enrollment 13 . Tortuous GSV , , opinion investigator , limit catheter placement require one primary access site . 14 . Aneurysm target vein local diameter &gt; 12 mm 15 . Significant , incompetent , ipsilateral small saphenous , intersaphenous anterior accessory great saphenous vein ( ) . 16 . Known sensitivity cyanoacrylate ( CA ) adhesives . 17 . Current participation another clinical study involve investigational agent treatment , within 30 day prior enrollment . 18 . Patients require bilateral treatment next 3 month 19 . Patients require additional ipsilateral treatment leg within 3 month follow treatment .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>GSV</keyword>
</DOC>